Stocks › MDGL
Madrigal Pharmaceuticals, Inc. (MDGL) stock analysis
SKIP 2% confidence · analysed Nov 4, 2026
On Nov 4, 2026, our model rated Madrigal Pharmaceuticals, Inc. (MDGL) SKIP with 2% confidence at a price of $396.32. That means the signals cancel out; the model sees no clear edge either way.
Technical picture
The 14-day RSI is 23, below 30, which is oversold territory: sellers have pushed hard recently. Oversold stocks often bounce, but they can stay weak for a while.
MACD is below its signal line, so short-term momentum is pointing down.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is 5.0x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure shows a bearish break of structure (BOS): price broke a recent swing low in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $569.44 and the swing low is $447.01; traders often treat these as resistance and support.
Fundamentals
The company reports a profit margin of -25.3% and revenue growth of +71.2%.
In its latest quarter it earned $1.83 per share, which beat the $-0.87 analysts expected, with revenue +71.2% year over year.
Wall Street's average rating is 1.3 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $685.22.
The model's one-paragraph read
No clear edge (SKIP) — composite score +0.02 (SKIP). Technicals: RSI 23.41, MACD bearish, price below SMA50. Fundamentals: margin -25.3%, revenue growth 71.2%. Financial results: YoY revenue +71.2%, last EPS surprise +310.3%. Smart Money Concepts: BOS bearish (trend continuation), equal lows below (resting liquidity). FinGPT news read: positive. Reference price $396.32; no trade levels (SKIP).
Past ratings for MDGL
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 4, 2026 | SKIP | 2% | $396.32 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on MDGL
- Nov 3, 2026: MDGL Stock Hits Fresh 52-Week Low On Near-Term Profitability Concerns, But Citi Sees Over 75% Upside (Stocktwits)
- Nov 3, 2026: Madrigal Turns Its First Profit On Rezdiffra Strength, But Slowing Growth Rates And 2027 Pricing Pressure Keep The Debate Alive (Earnings Whispers)
- Nov 3, 2026: How Did Madrigal Pharmaceuticals Turn a $114 Million Loss Into a Q3 Profit as Rezdiffra Sales Surpassed $1 Billion? (InvestorsHub)
- Nov 3, 2026: MediWound's EscharEx Strategy May Be Ahead of the Game as FDA Puts Chronic Wounds in Focus (Nasdaq: MDWD) (FinanceWire)
- Nov 3, 2026: Madrigal: Q3 Earnings Snapshot (Associated Press)
- Nov 3, 2026: Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
Frequently asked questions
Is MDGL a buy right now?
As of Nov 4, 2026, our automated model rates Madrigal Pharmaceuticals, Inc. (MDGL) SKIP with 2% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.